Interpretation of the adrenocortical carcinomas and malignant phaeochromocytomas:ESMO-EURA-CAN clinical practice guidelines for diagnosis,treatment and follow-up
Adrenocortical carcinoma and malignant pheochromocytoma are classified as rare diseases because of their low incidence,but seriously threaten human health and life expectancy because of their high degree of malignancy.At present,there is only a consensus of experts on adrenal cortical cancer in China,and there is no Chinese guideline formulated by multidisciplinary experts.Therefore,the study of relevant guidelines can provide important guiding significance for the treatment of these diseases.The European Soci-ety of Physicians of Oncology and the European Rare Adult Solid Cancer Reference Network have jointly pub-lished the adrenocortical carcinomas and malignant phaeochromocytomas:ESMO-EURACAN clinical practice guidelines for diagnosis,treatment,and follow-up,based on new clinical evidence.This article will compre-hensively interpret the diagnosis,staging evaluation,treatment management,and follow-up of this disease according to the latest research progress.
NETL
NSTL
万方数据
